Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HALO EM: Fremanezumab in episodic migraine
NCT02629861Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of fremanezumab in migraine, sponsored by Teva Pharmaceutical Industries Ltd.. Started Mar 2016; status: completed.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02629861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629861.